rs6234 — PCSK1 PCSK1 Q665E (Gln665Glu)

PCSK1 Q665E — When the Prohormone Scissors Lose Their Edge

Inside your pancreas, gut, and hypothalamus sits a molecular enzyme that is essential for activating three of the most important metabolic hormones in your body. Prohormone convertase 1/3 (PC1/3)¹¹ Prohormone convertase 1/3 (PC1/3)
Encoded by the PCSK1 gene on chromosome 5; a serine protease that cleaves inactive prohormone precursors at specific paired basic amino acid sites to release biologically active peptides cuts proinsulin into insulin, cleaves POMC into the satiety peptide alpha-MSH, and processes proglucagon into GLP-1, the incretin that amplifies insulin release after meals. The rs6234 variant — encoding a Gln-to-Glu substitution at position 665 of PC1/3 — sits in the enzyme's C-terminal domain, the region that governs its proper folding and stability.

The Mechanism

The Q665E amino acid change (plus one other: S690T encoded by the nearby rs6235) alters the C-terminal propeptide of PC1/3. This domain acts as an intramolecular chaperone — it guides the newly synthesized enzyme into its active conformation. Cell-based studies²² Cell-based studies
Mbikay et al. Effects of rs6234/rs6235 and rs6232/rs6234/rs6235 PCSK1 SNP clusters on proprotein convertase 1/3 biosynthesis and activity. Mol Genet Metab, 2011 show that the double-variant (Q665E/S690T) isoform undergoes accentuated proteolytic processing at the C-terminus compared to the common form. The proposed consequence is subtle in vivo instability: a C-terminally truncated PC1/3 is known to be less stable, creating a partial enzyme deficit in the endocrine and neuroendocrine cells where the prohormone processing that controls satiety and glucose homeostasis takes place.

The downstream effects converge on three pathways simultaneously. First, impaired proinsulin-to-insulin conversion: beta cells secrete more uncleaved precursor per secretory event, raising the circulating proinsulin-to-insulin ratio. Second, reduced POMC cleavage: less alpha-MSH is generated in hypothalamic neurons, blunting the melanocortin-4 receptor (MC4R) satiety signal that normally tells the brain to stop eating. Third, potentially reduced GLP-1 generation from proglucagon in intestinal L cells, modifying the incretin amplification of postprandial insulin release.

The Evidence

The variant was first identified as an obesity risk locus³³ first identified as an obesity risk locus
Benzinou et al. Common nonsynonymous variants in PCSK1 confer risk of obesity. Nature Genetics, 2008 in a meta-analysis of 13,659 Europeans across eight independent cohorts. The Q665E-S690T haplotype reached p = 2.31 × 10⁻¹², and the effect was replicated in all eight cohorts. The largest subsequent analysis — Nead et al. 2015⁴⁴ Nead et al. 2015
Meta-analysis of up to 331,175 individuals including GWAS consortia and custom arrays; most comprehensive assessment of common PCSK1 variants — confirmed OR = 1.07 (95% CI 1.04–1.10, p = 3.00 × 10⁻⁷) for obesity and a small but significant BMI effect of 0.02 units per allele (p = 5.57 × 10⁻⁴). Childhood and adolescent carriers show stronger effects (OR ~1.13) than adults (OR ~1.06), consistent with the enzyme's role in growth and early metabolic programming.

The impaired prohormone processing is not just theoretical. Heni et al. 2010⁵⁵ Heni et al. 2010
1,498 German subjects with detailed OGTT and hyperinsulinemic-euglycemic clamp studies; rs6235 (in complete LD with rs6234) directly measured an 8% higher proinsulin area-under-the-curve and elevated proinsulin-to-insulin ratio in C-allele carriers during an oral glucose tolerance test — demonstrating that the reduced enzyme activity translates into measurably impaired prohormone conversion under real metabolic challenge. The effect is modest but detectable even at population scale, pointing to the enzyme operating near capacity during peak postprandial demand.

Importantly, the association is largely absent in East Asian populations (OR ~1.00 in the Nead meta-analysis) but present in Caucasians, Hispanics, and Africans. This population-specific pattern has not been fully explained but may reflect differences in haplotype background or diet-gene interactions.

Practical Actions

For C-allele carriers, the primary dietary lever is glycemic load management. When meals generate large postprandial glucose peaks, pancreatic beta cells must mount large proinsulin secretory bursts — and in carriers of this variant, those bursts are converted to active insulin less efficiently. Spreading carbohydrate intake across smaller meals and choosing lower-glycemic sources reduces the secretory burden per event. High dietary protein also matters: protein-rich meals stimulate PYY and CCK satiety pathways that are PC1/3-independent, providing a route to satiety signaling that bypasses the impaired POMC-to-alpha-MSH axis.

Monitoring the proinsulin-to-insulin ratio (if available) and fasting proinsulin levels provides the most genotype-specific metabolic readout for this variant — more informative than HbA1c alone, which captures downstream glycemic control without revealing the underlying prohormone processing burden.

Interactions

rs6234 and rs6235 are in near-complete linkage disequilibrium and form an obligate haplotype — carriers of the rs6234 C allele almost always also carry the rs6235 T allele (S690T), and the two changes together constitute the functional isoform studied in the literature. The intronic variant rs10515237 (already in the GeneOps catalog) is in moderate LD (r² ≈ 0.84 in Europeans) with this haplotype and captures much of the same signal; rs6234 provides the direct coding-variant readout.

A third variant, rs6232 (N221D), forms an independent, rarer PCSK1 haplotype with stronger functional impairment than Q665E-S690T alone. Carriers of both rs6232 and rs6234 risk alleles (within the same gene) have additive reductions in PC1/3 activity. Downstream, the MC4R variant rs17782313 further modifies the obesity risk profile: rs6234 reduces the alpha-MSH signal generated from POMC; MC4R risk allele carriers have reduced receptor sensitivity to that signal. Carrying both is a plausible double-impairment scenario in the melanocortin satiety axis.